We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.00 | 10.30 | 10.80 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.71M | -11.11M | -0.0441 | -2.72 | 30.27M |
TIDMC4XD
RNS Number : 0552A
C4X Discovery Holdings PLC
18 January 2024
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Board Change
18 January 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that Mario Polywka, Non-Executive Director, has stepped down from the Board of Directors with immediate effect in order to focus on his recent appointment as Interim Chief Executive Officer of Evotec SE.
The Company intends to appoint a replacement Non-Executive Director and a further announcement will be made in due course.
Clive Dix, Interim Executive Chairman and Chief Executive Officer of C4X Discovery, said : "It has been a pleasure working with Mario since he joined the Board in 2021 and during this time C4X Discovery has benefitted from his deep industry insights and experience. We wish him all the best in his new role."
- Ends -
Contacts
C4X Discovery Holdings Mo Noonan, Communications +44 (0)787 6444977 Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) +44 (0)20 7886 2500 Rupert Dearden (Corporate Broking) C4X Discovery Media - ICR Consilium Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700 C4X Discovery Holdings
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world--leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.
For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAQDLFFZFLZBBL
(END) Dow Jones Newswires
January 18, 2024 02:00 ET (07:00 GMT)
1 Year C4x Discovery Chart |
1 Month C4x Discovery Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions